• 7 July 2010
  • News
  • By

Adopts stratagy of value-addition


Head: Sushil Mehta (MD)
Business: Manufactures and markets fine chemicals and lab kits
Start-up Year:2005
Address: A-3, Okhla Industrial area, Phase-I, New Delhi-110020
Tel: +91-11-41609171-75
Fax: +91-11-41609189
Website: www.rfcl.in

Life Sciences Business
(in Rs Crore)

Rs 93.23 Crore

RFCL is aggressively building its business with the support of R&D, product development and manufacturing to offer value-added products and services to the customers
With the surge of investments, RFCL looks forward to grow at a CAGR of 23 percent in next four years

RFCL Limited, owned by ICICI Venture Funds Management Company and managed by a group of professionals, focuses on two strategic business units – Rankem Scientific Laboratory Solutions and Diagnova. These two business segments cover a range of customer segments including pharma, biotech, R&D labs, food processing, in vitro diagnostic facilities in clinical labs, hospitals, and nursing homes.

RFCL has recorded a CAGR of over 25 percent in sales revenue for the last four years. However, for the fiscal 2009-10, the company's revenue stood at Rs 93.23 crore as compared to Rs 92.21 crore last year, when the company had achieved a phenomenal growth clocking Rs 34.04 crore in fiscal 2007-08.

Driven by its vision of “Leveraging science to provide solutions for a better life”, RFCL is aggressively building both its businesses backed by R&D, product development and manufacturing to offer value added products and services to its target customers. The company has recently unveiled its new mid-term plan, Sprint 2014, which will enable RFCL to grow at a CAGR of 23 percent for the next four years.

In micro-life portfolio (dehydrated culture media), Rankem has added 64 products, which will give wider spectrum to different application areas.

In molecular biology segment, the addition of 47 products will be completing the basket of fermentation area, where the purity and accuracy is now defined at upstream process. According to new practices in fermentation technology, now more emphasis is given to upstream process to reduce the end product cost and to increase efficiency of the drug.

RFCL also entered into a strategic partnership with Integrated DNA Technologies (IDT), US, for the marketing of custom nucleic acids to the Indian researchers.

The company has plans to invest on building in-house manufacturing for diagnostic products and laboratory chemicals. The company has already commissioned a dedicated manufacturing plant for diagnostics in Dehradun.

In addition, a new lab chemical manufacturing plant is currently under erection stages at Panoli, Gujarat.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email